DADLE

{{Short description|Synthetic opioid analgesic peptide}}

{{chembox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 451771395

| ImageFile=2-D-Alanine-5-D-leucine-enkephalin.png

| ImageSize=250px

| IUPACName=(2R)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid

| OtherNames= • [D-Ala², D-Leu⁵]-Enkephalin
• L-Tyrosyl-D-alanylglycyl-L-phenylalanyl-D-Leucine
• N-(N-(N-(N-L-tyrosyl-D-alanyl)glycyl)-L-phenylalanyl)-D-Leucine
• Tyr-D-Ala-Gly-Phe-D-Leu-OH

|Section1={{Chembox Identifiers

| CASNo_Ref = {{cascite|correct|??}}

| CASNo=63631-40-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = HB4QD9GL6F

| PubChem=6917707

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 5292936

| InChI = 1/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1

| InChIKey = ZHUJMSMQIPIPTF-IBURTVSXBS

| StdInChI_Ref = {{stdinchicite|changed|chemspider}}

| StdInChI = 1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1

| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}

| StdInChIKey = ZHUJMSMQIPIPTF-IBURTVSXSA-N

| SMILES=N[C@H](C(N[C@H](C)C(NCC(N[C@@H](CC1=CC=CC=C1)C(N[C@H](CC(C)C)C(O)=O)=O)=O)=O)=O)CC2=CC=C(O)C=C2

}}

|Section2={{Chembox Properties

| C=29|H=39|N=5|O=7

| Appearance=

| Density=

| MeltingPt=

| BoilingPt=

| Solubility=

}}

|Section3={{Chembox Hazards

| MainHazards=

| FlashPt=

| AutoignitionPt=

}}

}}

DADLE ([D-Ala², D-Leu⁵]-Enkephalin) is a synthetic opioid peptide with analgesic properties. Although it is often considered a selective δ-opioid receptor agonist, it also binds to the μ₁ subtype of μ-opioid receptors.

Treatment with DADLE results in transient depression of mean arterial blood pressure and heart rate.{{Cite web |url=http://www.online-medical-dictionary.org/Leucine%2D2%2DAlanine+Enkephalin.asp?q=Leucine%2D2%2DAlanine+Enkephalin |title=Medical Dictionary Online |access-date=2007-11-10 |archive-url=https://web.archive.org/web/20070828004826/http://www.online-medical-dictionary.org/Leucine%2D2%2DAlanine+Enkephalin.asp?q=Leucine%2D2%2DAlanine+Enkephalin |archive-date=2007-08-28 |url-status=dead }}[https://archive.today/20070813174048/http://cancerweb.ncl.ac.uk/cgi-bin/omd?enkephalin,+leucine-2-alanine Online Medical Dictionary, enkephalin, leucine-2-alanine]

Its peptide sequence is Tyr-D-Ala-Gly-Phe-D-Leu.